Man-16
CMFTe004-A
General#
Cell Line |
|
hPSCreg Name | CMFTe004-A |
Alternative name(s) |
Man-16
|
Cell line type | Human embryonic stem cell (hESC) |
Last update | 22nd May 2019 |
User feedback | |
Provider |
|
Generator | Central Manchester and Manchester Children's University Hospitals NHS (CMFT) |
Owner | Central Manchester NHS Foundation Trust (CMFT) |
Distributors | |
Derivation country | United Kingdom |
External Databases |
|
BioSamples | SAMEA104615891 |
Cellosaurus | CVCL_BW70 |
CLO | CLO_0101455 |
General Information |
|
Publications | |
* Is the cell line readily obtainable for third parties? |
Yes Clinical: allowed
Commercial: not allowed
|
Donor Information#
General Donor Information |
|
Sex | male |
Phenotype and Disease related information (Donor) |
|
Diseases | No disease was diagnosed.
|
Is the medical history available upon request? | Yes |
Is clinical information available? | Yes |
Karyotyping (Donor) |
|
Has the donor karyotype been analysed? |
Yes
|
Other Genotyping (Donor) |
|
Is there genome-wide genotyping or functional data available? |
Yes
Array CGH
|
External Databases (Donor) |
|
BioSamples | SAMEA104619381 |
Ethics#
Was the embryo established purely for research purposes? | No |
Have both parents consented to the use of the embryo for ESC derivation? | Yes |
Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes |
Was the consent voluntarily given? | Yes |
Alternatives to consent are available? | Yes |
Alternatives to consent | |
Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | anonymised |
Does consent explicitly allow the derivation of pluripotent stem cells? | Yes |
Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No |
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | Yes |
Name of accrediting authority involved? | HTA, HFEA, and UK Stem Cell Bank |
Approval number | HTA Licence number: 22627, HFEA Licence number: R0171-4-b. UKSCB approval number: SCSC14-25 |
hESC Derivation#
Date of derivation | 2012-09-18 |
Embryo stage | Blastula with ICM and Trophoblast |
Supernumerary embryos from IVF treatment? |
Yes
Separation of research and IVF treatment?
Yes |
PGD Embryo? |
No |
Expansion status |
3![]() |
ICM morphology |
C![]() |
Trophectoderm morphology |
g![]() |
ZP removal technique | Chemical |
Cell isolation | Mechanical |
Cell seeding | Isolated ICM |
Derived under xeno-free conditions? |
Yes |
Derivation under GMP? |
Yes |
Available as clinical grade? |
Yes |
Culture Conditions#
Surface coating | CELLstart | |||||||||
Feeder cells |
Human Dermal Fibroblast Cellfinder Ont Id: CELDA_000001419 |
|||||||||
Passage method | Mechanically | |||||||||
O2 Concentration | 20 % | |||||||||
CO2 Concentration | 5 % | |||||||||
Medium |
mTeSR™ 2
Supplements
|
|||||||||
Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | Unknown |
|||||||||
Has Rock inhibitor (Y27632) been used at cryo previously with this cell line? | Unknown |
|||||||||
Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | Unknown |
Characterisation#
Analysis of Undifferentiated Cells
Marker | Expressed | Immunostaining | RT-PCR | FACS | Enzymatic Assay | Expression Profiles |
NANOG |
Yes |
|
||||
POU5F1 (OCT-4) |
Yes |
|
||||
SOX2 |
Yes |
|
||||
SSEA-1 |
No |
|
||||
SSEA-4 |
Yes |
|
||||
TRA 1-60 |
Yes |
|
Differentiation Potency
In vitro spontaneous differentiation
Marker | Expressed |
GATA Binding Protein 6 |
Yes |
FOXA2 |
Yes |
In vitro spontaneous differentiation
Marker | Expressed |
Actin, Alpha 2, Smooth Muscle, Aorta |
Yes |
Vimentin |
Yes |
In vitro spontaneous differentiation
Marker | Expressed |
Tubulin Beta 3 Class III |
Yes |
Neurofilament, light polypeptide |
Yes |
Microbiology / Virus Screening |
|
HIV 1 | Negative |
HIV 2 | Negative |
Hepatitis B | Negative |
Hepatitis C | Negative |
Mycoplasma | Negative |
Genotyping#
Karyotyping (Cell Line) |
|
Has the cell line karyotype been analysed? |
Yes
Normal Male 46 XY
Passage number: 16
Karyotyping method:
G-Banding
|
Other Genotyping (Cell Line) |
|
Is there genome-wide genotyping or functional data available? |
Yes
Array CGH
|
Login to share your feedback, experiences or results with the research community.